Zacks Investment Research upgraded shares of Xencor (NASDAQ:XNCR) from a sell rating to a hold rating in a research note published on Saturday.
According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
Several other equities analysts have also recently commented on XNCR. BidaskClub upgraded Xencor from a buy rating to a strong-buy rating in a research report on Friday, March 9th. Cantor Fitzgerald restated an overweight rating and set a $37.00 target price on shares of Xencor in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Xencor presently has an average rating of Buy and a consensus price target of $36.75.
Shares of Xencor (XNCR) opened at $32.27 on Friday. Xencor has a one year low of $18.55 and a one year high of $34.63. The stock has a market capitalization of $1,451.67, a price-to-earnings ratio of -31.03 and a beta of 1.50.
In related news, insider Paul A. Foster sold 5,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.01, for a total transaction of $125,050.00. Following the completion of the transaction, the insider now directly owns 7,419 shares in the company, valued at $185,549.19. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Edgardo Baracchini, Jr. sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $30.89, for a total value of $1,235,600.00. Following the transaction, the insider now owns 40,000 shares of the company’s stock, valued at $1,235,600. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,000 shares of company stock valued at $3,101,550. 4.14% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can grew its position in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares in the last quarter. Principal Financial Group Inc. purchased a new position in Xencor during the third quarter worth about $201,000. UBS Asset Management Americas Inc. purchased a new position in shares of Xencor in the 4th quarter worth about $205,000. Landscape Capital Management L.L.C. purchased a new position in shares of Xencor in the 4th quarter worth about $220,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Xencor in the 4th quarter worth about $278,000. Institutional investors and hedge funds own 79.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thestockobserver.com/2018/03/21/xencor-xncr-rating-increased-to-hold-at-zacks-investment-research.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.